The retrospective study included 36 eyes of 36 patients with a mean age of 67.8 years who underwent combined PDT with adjuvant Avastin (bevacizumab, Genentech); 33 eyes of 33 patients with a mean age of 65.6 years were treated with PDT alone.
Investigators assessed best corrected visual acuity, tonometry and fundus photos before treatment and at all follow-up points. Optical coherence tomography, fluorescein angiography and indocyanine green angiography were performed before treatment and at subsequent 3-month intervals.
At 3 months, mean logMAR BCVA had improved from 0.73 to 0.53 in the combined treatment group and from 0.79 to 0.72 in the monotherapy group. The between-group difference in treatment efficacy was statistically significant (P < .001) at 3 months.
Improvements in BCVA were insignificant after 21 months in the combined treatment group and 15 months in the monotherapy group. The between-group difference in efficacy was insignificant after 6 months, the authors said.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.